OncoSec Medical Inc (OTCMKTS:ONCS) has been taking part in a number of conferences lately. The company made the announcement of its presence at a number of conferences being held in May. The list contains a number of conferences relating to the company’s business plans and its product developments. The first one in the list is PEGS, being held in Boston, where the company CSO, Robert H. Pierce, would represent OncoSec.
The company is the maker of ImmunoPulse IL-12. ImmunoPulse is a cancer treating drug, which increases tumor infiltrating lymphocytes. The initial results of the company showed what was expected of the drug. The drug is set to become the flagship product for the company and will be presented at PEGS, where it was suggested that it should be combined with anti-PD 1.
Dr. Pierce had been invited to the PEGS conference, to give his presentation “Taking the Fight to the Tumor”. In it he had described the role of intratumoral immunotherapy as a means to reveal antigens and drive anti-tumor responses. He took the opportunity to reveal the preliminary results of his company’s drug. The CEO of OncoSec Medical Inc (OTCMKTS:ONCS), Punit Dhillon, stated that the results were promising and as further trials are conducted, the public can expect more promising results at future conferences.
PEGS is the prime event for antibody and protein researchers from the biologics industry. The conference is aimed at sharing insights and best practices amongst the researchers. Additionally, industrial trends and current challenges are also part of the conversations. Apart from PEGS, the company is set to take part in Macrum Microcap Confrence and Sachs Immuno-Oncology Investment forum. The company will be represented by CEO, Punit Dhillon, in both conferences, where he will present the corporate overview of his company.
